MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Cancer Network' source. Wed, 08 Feb 2012 08:41:22 +0100 http://www.medworm.com/index.php?rid=5666835&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fgastrointestinal-stromal-tumor%2Fcontent%2Farticle%2F10165%2F2028035%3FCID%3Drss The FDA has granted imatinib full approval as an adjuvant treatment following surgical removal of CD117-positive gastrointestinal stromal tumors in adult patients. This comes after results from a phase III trial showed that patients taking imatinib for 36 months had a 5-year overall survival of 92%, compared to 82% for those patients who took the drug for the standard 12 months of treatment. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5666835 Wed, 08 Feb 2012 13:00:02 +0100 5666835 http://www.medworm.com/index.php?rid=5666837&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fimage-iq%2Fderm%2Fcontent%2Farticle%2F10165%2F2027753%3FCID%3Drss A 68-year-old woman presented with a mass on the scalp which had been present for approximately 7 years. An incisional biopsy of the scalp mass and excisional biopsy of the lymph node both revealed basal cell carcinoma, micronodular histologic subtype. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5666837 Mon, 06 Feb 2012 12:00:00 +0100 5666837 http://www.medworm.com/index.php?rid=5666836&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fprostate-cancer%2Fcontent%2Farticle%2F10165%2F2027790%3FCID%3Drss Initial results of a multicenter trial show that 2 biomarkers, PCA3 and T2-ERG, are found at high levels in prostate cancer compared to noncancerous prostate cells and correlate well with 2 indicators of aggressive prostate cancer, tumor volume and Gleason score. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5666836 Mon, 06 Feb 2012 12:00:00 +0100 5666836 http://www.medworm.com/index.php?rid=5659463&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fkidney-cancer%2Fcontent%2Farticle%2F10165%2F2026106%3FCID%3Drss CancerNetwork speaks with Dr. Michael Atkins, who has extensive clinical experience in kidney cancer and development of various new treatments, and is presenting this weekend during the renal cancer translational science session at the American Society of Clinical Oncology 2012 Genitourinary Cancers Symposium. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5659463 Sun, 05 Feb 2012 13:00:02 +0100 5659463 http://www.medworm.com/index.php?rid=5647243&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fprostate-cancer%2Fcontent%2Farticle%2F10165%2F2024765%3FCID%3Drss It is still difficult to gauge the probability that a low-risk prostate cancer patient may be upgraded to a higher prostate cancer stage. Researchers at Vanderbilt University Medical Center have now determined that smaller prostates were more likely to evolve into more serious, aggressive disease. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5647243 Thu, 02 Feb 2012 13:00:01 +0100 5647243 http://www.medworm.com/index.php?rid=5647244&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fmelanoma-skin-cancer%2Fcontent%2Farticle%2F10165%2F2024253%3FCID%3Drss The U.S. Food and Drug Administration (FDA) announced the approval of vismodegib (Erivedge), for the treatment of advanced basal cell carcinoma, the most common type of skin cancer, for patients who are not eligible for surgery or radiation, and for metastatic disease. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5647244 Tue, 31 Jan 2012 12:00:00 +0100 5647244 http://www.medworm.com/index.php?rid=5647246&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcolorectal-cancer%2Fcontent%2Farticle%2F10165%2F2022830%3FCID%3Drss Metastatic melanomas that harbor the V600E mutation in the BRAF gene respond rapidly to vemurafenib (Zelboraf), the BRAF V600E inhibitor. But While vemurafenib results in a response in about 80% of melanoma patients, the clinical response among CRC patients is not greater than 5%. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5647246 Mon, 30 Jan 2012 12:00:00 +0100 5647246 http://www.medworm.com/index.php?rid=5647245&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Frcc%2Fcontent%2Farticle%2F10165%2F2023818%3FCID%3Drss The U.S. Food and Drug Administration (FDA) has approved the angiogenesis blocker axitinib (Inlyta), a twice daily oral drug, as a second-line treatment for patients with advanced renal cell carcinoma. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5647245 Mon, 30 Jan 2012 12:00:00 +0100 5647245 http://www.medworm.com/index.php?rid=5638212&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcolorectal-cancer%2Fcontent%2Farticle%2F10165%2F2023182%3FCID%3Drss A study published earlier this month identifies specific colorectal tumors that are less responsive to chemotherapy. Researchers at the University of Magdeburg show that the hypermethylation of the transcription factor AP-2 epsilon (TFAP2E) gene results in lower expression of the TFAP2E protein and upregulation of the DKK4 gene, a gene which has been previously associated with resistance to the chemotherapy fluorouracil. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5638212 Sun, 29 Jan 2012 13:00:01 +0100 5638212 http://www.medworm.com/index.php?rid=5628194&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fbreast-cancer%2Fcontent%2Farticle%2F10165%2F2021313%3FCID%3Drss Breast cancer survivorship continues to rise, but the long-lasting psychosocial and quality-of-life changes that occur after treatment need to be studied, as treatment outcomes can lead to negative side effects that outlast the treatment. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5628194 Thu, 26 Jan 2012 13:00:01 +0100 5628194 http://www.medworm.com/index.php?rid=5619783&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fmelanoma-skin-cancer%2Fcontent%2Farticle%2F10165%2F2020914%3FCID%3Drss In a rare case where the side effect of a cancer treatment can be explained through molecular studies, researchers have identified the reason behind the frequent skin lesion side effect among metastatic melanoma patients that take the newly approved drug vemurafenib. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5619783 Mon, 23 Jan 2012 13:00:02 +0100 5619783 http://www.medworm.com/index.php?rid=5628195&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fimage-iq%2Fderm%2Fcontent%2Farticle%2F10165%2F2021169%3FCID%3Drss A 28-year-old, slightly obese Caucasian woman presented with a long-standing history of intermittently painful “bumps” on both shoulders and her upper back. Review of systems disclosed regular but very heavy menstrual periods, often lasting for 7 to 9 days, and chronic constipation. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5628195 Mon, 23 Jan 2012 12:00:00 +0100 5628195 http://www.medworm.com/index.php?rid=5608302&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fovarian-cancer%2Fcontent%2Farticle%2F10165%2F2020100%3FCID%3Drss A new study has made a step forward toward better characterization of sporadic ovarian tumors by identifying their DNA repair protein expression profile. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5608302 Fri, 20 Jan 2012 13:00:02 +0100 5608302 http://www.medworm.com/index.php?rid=5608303&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpancreatic-cancer%2Fcontent%2Farticle%2F10165%2F2019758%3FCID%3Drss Researchers in Sweden who analyzed several prospective studies found an increased risk of pancreatic cancer associated with processed meat consumption. They also found that eating red meat is linked to pancreatic cancer among men. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5608303 Wed, 18 Jan 2012 12:00:00 +0100 5608303 http://www.medworm.com/index.php?rid=5597058&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fchronic-myeloid-leukemia%2Fcontent%2Farticle%2F10165%2F2017594%3FCID%3Drss The results of the 2-year follow-up of the dasatinib DASISION phase III trial show the continued superiority of the drug compared to imatinib. The results provide further support for treatment of first-line chronic phase chronic myeloid leukemia patients that harbor the Philadelphia chromosome. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5597058 Tue, 17 Jan 2012 13:00:01 +0100 5597058 http://www.medworm.com/index.php?rid=5608315&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fleukemia-lymphoma%2Fcontent%2Farticle%2F10165%2F2016539%3FCID%3Drss The aim of this review is twofold: to summarize descriptions of the clinical presentation provided in published series in order to help clinicians recognize and treat patients, and to discuss diagnostic difficulties faced by hematopathologists when dealing with these lesions and others in the differential diagnosis that must be distinguished from one another. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5608315 Tue, 17 Jan 2012 12:00:00 +0100 5608315 http://www.medworm.com/index.php?rid=5608314&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fleukemia-lymphoma%2Fcontent%2Farticle%2F10165%2F2016601%3FCID%3Drss Until we fully engage in understanding the biologic mechanisms that separate NMZL from other indolent NHLs, however, we will continue to deliver “impersonalized medicine” that does not exploit the unique properties of the former. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5608314 Tue, 17 Jan 2012 12:00:00 +0100 5608314 http://www.medworm.com/index.php?rid=5608313&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fprostate-cancer%2Fcontent%2Farticle%2F10165%2F2016381%3FCID%3Drss We have entered a period of accelerated drug development and optimism in the care of advanced prostate cancer. The treatment paradigm for these patients is rapidly evolving, with future study needed to define the optimal sequencing and potential combinations of these new agents. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5608313 Tue, 17 Jan 2012 12:00:00 +0100 5608313 http://www.medworm.com/index.php?rid=5608312&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fprostate-cancer%2Fcontent%2Farticle%2F10165%2F2016386%3FCID%3Drss After several decades with only modest changes in the therapeutic paradigm, rapid progress in understanding the biology of advanced prostate cancer has been translated into more accurate terminology, such as “castration-resistant” (as opposed to “hormone-refractory” or “androgen-independent”) prostate cancer, as well as clinically meaningful therapeutic developments. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5608312 Tue, 17 Jan 2012 12:00:00 +0100 5608312 http://www.medworm.com/index.php?rid=5608311&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fprostate-cancer%2Fcontent%2Farticle%2F10165%2F2016391%3FCID%3Drss These are, indeed, exciting times for patients with metastatic prostate cancer and the clinicians who care for them. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5608311 Tue, 17 Jan 2012 12:00:00 +0100 5608311 http://www.medworm.com/index.php?rid=5608310&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpractice%2Fcontent%2Farticle%2F10165%2F2016361%3FCID%3Drss This article addresses some of the most common major challenges in oncologist-patient communication with a nuanced approach to the concepts of autonomy, paternalism, and culture. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5608310 Tue, 17 Jan 2012 12:00:00 +0100 5608310 http://www.medworm.com/index.php?rid=5608309&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpractice%2Fcontent%2Farticle%2F10165%2F2016366%3FCID%3Drss In this paper, Dr. Cherny beautifully reviews how to balance the patient's right to be adequately informed about his or her disease with the powerful cultural beliefs held in many parts of the world. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5608309 Tue, 17 Jan 2012 12:00:00 +0100 5608309 http://www.medworm.com/index.php?rid=5608308&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpractice%2Fcontent%2Farticle%2F10165%2F2016371%3FCID%3Drss Of all diseases, cancer probably elicits the strongest emotional reaction, and this is even more true if one is an affected patient. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5608308 Tue, 17 Jan 2012 12:00:00 +0100 5608308 http://www.medworm.com/index.php?rid=5608307&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpractice%2Fcontent%2Farticle%2F10165%2F2016376%3FCID%3Drss Beginning with its provocative opening case vignette, Nathan Cherny's article provides an opportunity for us to reflect on and possibly redirect our own attitudes and habits regarding difficult ethical issues in communication with our patients and their families, especially in the setting of cultural and religious diversity. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5608307 Tue, 17 Jan 2012 12:00:00 +0100 5608307 http://www.medworm.com/index.php?rid=5608306&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fbreast-cancer%2Fcontent%2Farticle%2F10165%2F2016352%3FCID%3Drss Treatment of HER2-positive cancers has improved rapidly over the past decade, and the pace of progress continues to accelerate. The advances have been fueled in part by the conduct of neoadjuvant studies, which have aided in the development of novel therapies and more effective combination regimens. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5608306 Tue, 17 Jan 2012 12:00:00 +0100 5608306 http://www.medworm.com/index.php?rid=5608305&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fbreast-cancer%2Fcontent%2Farticle%2F10165%2F2016316%3FCID%3Drss This article provides a comprehensive summary of the knowledge gained from recent neoadjuvant trials conducted with agents targeting HER2, and will put them into perspective with current treatment recommendations from American and European guidelines. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5608305 Tue, 17 Jan 2012 12:00:00 +0100 5608305 http://www.medworm.com/index.php?rid=5608304&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fbreast-cancer%2Fcontent%2Farticle%2F10165%2F2016337%3FCID%3Drss It may not be appropriate, nor always considered standard, to recommend neoadjuvant chemotherapy for all patients for whom adjuvant therapy was recommended before surgery. Indeed, tumor size and nodal status play a role, as do hormone receptors, in determining the appropriate extent of adjuvant therapy. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5608304 Tue, 17 Jan 2012 12:00:00 +0100 5608304 http://www.medworm.com/index.php?rid=5581147&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fmelanoma-skin-cancer%2Fcontent%2Farticle%2F10165%2F2016273%3FCID%3Drss A large cohort study shows that women on antiestrogen therapy have a lower risk of melanoma. In a study of 7360 women diagnosed with breast cancer between 1980 and 2005, 54% were given supplemental antiestrogen therapy. The rate of cutaneous melanoma was 60% higher for those women not taking antiestrogen supplements compared with the expected rate of melanoma incidence based on age and other factors. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5581147 Fri, 13 Jan 2012 13:00:02 +0100 5581147 http://www.medworm.com/index.php?rid=5581148&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fimage-iq%2Fderm%2Fcontent%2Farticle%2F10165%2F2014564%3FCID%3Drss A 46-year-old woman presented for medical evaluation due to a 2-month history of increasing difficulty in ambulation, especially getting up out of a chair or climbing stairs. She had also noticed swelling and discoloration of both upper eyelids (as depicted). (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5581148 Mon, 09 Jan 2012 12:00:00 +0100 5581148 http://www.medworm.com/index.php?rid=5572011&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fblog%2Fcontent%2Farticle%2F10165%2F2013974%3FCID%3Drss The end of another year usually inspires us to interesting if not profound reflections, but in my case I am just trying to remember any rainbows of wisdom that appeared to me during 2011. Those who care for cancer patients cannot help but learn new insights about life and death, and since aphorisms are valuable only if spread, why not share a few? (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5572011 Sun, 08 Jan 2012 13:00:02 +0100 5572011 http://www.medworm.com/index.php?rid=5572012&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpancreatic-cancer%2Fcontent%2Farticle%2F10165%2F2013894%3FCID%3Drss Inherited mutations in the ataxia telangiectasia mutated (ATM) gene increase the odds of developing pancreatic cancer according to a new study. While there is predisposition for pancreatic cancer with up to 10% of cases occurring among families with a history of the disease, the genetic basis for this had not been previously discovered. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5572012 Fri, 06 Jan 2012 12:00:00 +0100 5572012 http://www.medworm.com/index.php?rid=5572013&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Flung-cancer%2Fcontent%2Farticle%2F10165%2F2013794%3FCID%3Drss A new finding suggests that inhibiting the cytokine interleukin-17A, produced by inflammatory cells of the immune system, may be a novel approach in the treatment of lung tumors. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5572013 Thu, 05 Jan 2012 12:00:00 +0100 5572013 http://www.medworm.com/index.php?rid=5559610&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Flung-cancer%2Fcontent%2Farticle%2F10165%2F2012914%3FCID%3Drss A study has identified a gene fusion from a never-smoker lung cancer patient that may act as a driver in a subset of lung cancer cases. The results suggest that the newly identified fusion is not that rare and that the mutation exists in primary lung adenocarcinomas. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5559610 Wed, 04 Jan 2012 17:30:01 +0100 5559610 http://www.medworm.com/index.php?rid=5581150&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcancer-management%2Fhodgkin-lymphoma%2Farticle%2F10165%2F1802743%3FCID%3Drss This management guide covers the epidemiology, etiology and risk factors, signs and symptoms, diagnosis, pathology, staging and prognosis, and the treatment of Hodgkin lymphoma. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5581150 Sat, 31 Dec 2011 12:00:00 +0100 5581150 http://www.medworm.com/index.php?rid=5581149&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcancer-management%2Facute-leukemias%2Farticle%2F10165%2F1802772%3FCID%3Drss This treatment guide for acute leukemias covers the epidemiology, etiology and risk factors, signs and symptoms, diagnosis, and treatment of ALL, AML, and APL. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5581149 Sat, 31 Dec 2011 12:00:00 +0100 5581149 http://www.medworm.com/index.php?rid=5572019&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcolorectal-cancer%2Fcontent%2Farticle%2F10165%2F2010509%3FCID%3Drss Treatment for patients with locally advanced, resectable rectal cancer has clearly evolved, with significant refinements in preoperative assessment, surgical technique, and use of preoperative CMT. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5572019 Sat, 31 Dec 2011 12:00:00 +0100 5572019 http://www.medworm.com/index.php?rid=5572018&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcolorectal-cancer%2Fcontent%2Farticle%2F10165%2F2010514%3FCID%3Drss The exact role of combined-modality therapy and TAE of rectal cancer remains to be defined. Certainly the stakes are high, as studies have shown that the recurrence of locally excised rectal cancer is associated with worse long-term survival outcomes. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5572018 Sat, 31 Dec 2011 12:00:00 +0100 5572018 http://www.medworm.com/index.php?rid=5572017&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcolorectal-cancer%2Fcontent%2Farticle%2F10165%2F2010519%3FCID%3Drss Advances in the treatment of rectal cancer, such as TME and CMT, have lengthened survival time and enhanced the quality of life. However, radiation therapy may have a negative impact on quality of life, especially in males. Future research needs to focus not only on survival but also on postoperative quality of life. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5572017 Sat, 31 Dec 2011 12:00:00 +0100 5572017 http://www.medworm.com/index.php?rid=5572016&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fbladder-cancer%2Fcontent%2Farticle%2F10165%2F2010560%3FCID%3Drss Muscle-invasive bladder cancer is an aggressive and potentially lethal disease. Integration of multimodal therapies, improved surgical techniques, and utilization of targeted agents has tremendously improved outcomes. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5572016 Sat, 31 Dec 2011 12:00:00 +0100 5572016 http://www.medworm.com/index.php?rid=5572015&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fbladder-cancer%2Fcontent%2Farticle%2F10165%2F2010565%3FCID%3Drss Still missing in our treatment of bladder cancer are the tools to accurately predict response to a specific therapy, whether it be chemotherapy, radiation, or transurethral resection alone. Once we have these tools, we will be well on our way to applying a more intelligent, true personalized medicine approach to the treatment of this disease. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5572015 Sat, 31 Dec 2011 12:00:00 +0100 5572015 http://www.medworm.com/index.php?rid=5572014&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fbladder-cancer%2Fcontent%2Farticle%2F10165%2F2010570%3FCID%3Drss Patient selection based on a much more comprehensive biologic assessment of both host and tumor is likely the key to further advances in the treatment of all bladder cancer patients. Until such time, there can be no compromise in the careful application of the rigorous therapy required to optimize outcomes. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5572014 Sat, 31 Dec 2011 12:00:00 +0100 5572014 http://www.medworm.com/index.php?rid=5559616&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F2010540%3FCID%3Drss The past year in oncology was highlighted by the continuation of breakthroughs in targeted therapies—with new treatments receiving US Food and Drug Administration (FDA) approval for non–small-cell lung cancer (NSCLC), lymphoma, and melanoma. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5559616 Sat, 31 Dec 2011 12:00:00 +0100 5559616 http://www.medworm.com/index.php?rid=5559615&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fbone-metastases%2Fcontent%2Farticle%2F10165%2F2010550%3FCID%3Drss In addition to endeavors to develop new therapeutics, we should anticipate and prioritize studies that will address questions regarding the efficacy of combination therapy, timing and sequencing strategies, and the development of predictive markers to individualize and optimize therapy. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5559615 Sat, 31 Dec 2011 12:00:00 +0100 5559615 http://www.medworm.com/index.php?rid=5559614&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fbone-metastases%2Fcontent%2Farticle%2F10165%2F2010555%3FCID%3Drss We are seeing a new era in drug development with the identification of novel intra- and extracellular targets to which therapies are being directed. Perhaps more exciting is learning how to optimize standard therapies in combination with biologic agents and radiopharmaceuticals in order to target multiple pathways in prostate cancer growth. Stay tuned! (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5559614 Sat, 31 Dec 2011 12:00:00 +0100 5559614 http://www.medworm.com/index.php?rid=5559613&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F2009998%3FCID%3Drss While ONCOLOGY has continued to evolve along with the field of oncology—for example, it now addresses critical issues of science and socioeconomics—it has remained true to the founding principles. Perhaps largely for this reason, the journal continues to be widely read across the entire oncology community. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5559613 Sat, 31 Dec 2011 12:00:00 +0100 5559613 http://www.medworm.com/index.php?rid=5559612&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fbone-metastases%2Fcontent%2Farticle%2F10165%2F2010545%3FCID%3Drss This review will examine agents with potential activity in the palliation and treatment of skeletal metastases of PCa, and will weigh the clinical-outcomes evidence for and against their broad use. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5559612 Sat, 31 Dec 2011 12:00:00 +0100 5559612 http://www.medworm.com/index.php?rid=5559611&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fintegrative-oncology%2Fcontent%2Farticle%2F10165%2F2010005%3FCID%3Drss The active constituent of green tea extract is EGCG, which accounts for 40% of its total polyphenol content. Regular consumption of green tea may reduce the risk of hypertension and positively affect mood. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5559611 Sat, 31 Dec 2011 12:00:00 +0100 5559611 http://www.medworm.com/index.php?rid=5552158&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fmelanoma-skin-cancer%2Fcontent%2Farticle%2F10165%2F2010534%3FCID%3Drss For localized in-transit disease, less is more, with local destruction, excision, and intralesional therapy being the cornerstones of treatment. If local therapies fail or if distant disease arises, isolated limb perfusion and systemic therapy remain effective options. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5552158 Sat, 31 Dec 2011 01:30:02 +0100 5552158 http://www.medworm.com/index.php?rid=5552160&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fmelanoma-skin-cancer%2Fcontent%2Farticle%2F10165%2F2010524%3FCID%3Drss The management of in-transit metastases is challenging, since the treatments and extent of disease vary greatly based on the number, depth, location, and distribution of lesions, and on their biological behavior. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5552160 Fri, 30 Dec 2011 12:00:00 +0100 5552160 http://www.medworm.com/index.php?rid=5552159&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fmelanoma-skin-cancer%2Fcontent%2Farticle%2F10165%2F2010529%3FCID%3Drss While patients with in-transit disease represent a wide spectrum of disease that requires individualized therapy, great opportunity exists to learn from our treatment interventions in these individuals. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5552159 Fri, 30 Dec 2011 12:00:00 +0100 5552159 http://www.medworm.com/index.php?rid=5537504&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fbreast-cancer%2Fcontent%2Farticle%2F10165%2F2009882%3FCID%3Drss A study published in the journal Cancer shows that breast cancer survivors can experience problems with specific mental abilities up to several years after treatment. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5537504 Sun, 25 Dec 2011 01:30:01 +0100 5537504 http://www.medworm.com/index.php?rid=5537506&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcancer-management%2Fprimary-metastic-brain-tumors%2Farticle%2F10165%2F1802718%3FCID%3Drss This treatment guide covers the epidemiology, etiology and risk factors, signs and symptoms, screening for metastatic brain tumors, diagnosis, pathology, staging and prognosis, and treatment of primary and metastatic brain tumors. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5537506 Thu, 22 Dec 2011 12:00:00 +0100 5537506 http://www.medworm.com/index.php?rid=5537505&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcancer-management%2Fpain-management%2Farticle%2F10165%2F1802831%3FCID%3Drss This guide on pain management covers the medical evaluation, psychosocial assessment, subgrouping of patients, pharmacologic treatment, surgery for bone metastasis, radiation therapy, physical treatments, and ongoing care. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5537505 Thu, 22 Dec 2011 12:00:00 +0100 5537505 http://www.medworm.com/index.php?rid=5524227&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcancer-management%2Fnon-hodgkin-lymphoma%2Farticle%2F10165%2F1802748%3FCID%3Drss This management guide covers the epidemiology, etiology and risk factors, signs and symptoms, screening and diagnosis, staging and prognosis, and treatment of non-Hodgkin lymphoma. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5524227 Thu, 22 Dec 2011 01:30:02 +0100 5524227 http://www.medworm.com/index.php?rid=5524228&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcancer-management%2Ffluid-complications%2Farticle%2F10165%2F1802878%3FCID%3Drss This treatment guide on fluid complications covers the diagnosis, prognosis, and treatment of malignant pleural effusion, pericardial effusion, and malignant ascites. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5524228 Tue, 20 Dec 2011 12:00:00 +0100 5524228 http://www.medworm.com/index.php?rid=5524232&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fnurses%2Fcontent%2Farticle%2F10165%2F2008329%3FCID%3Drss A team of researchers from the University of Connecticut at Storrs and the National Cancer Institute, analyzing US national health data on more than 4,000 racially diverse adults aged 75 years and older, has concluded that despite “ambiguity of recommendations for this group,” cancer screening rates are high in this population. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5524232 Mon, 19 Dec 2011 12:00:00 +0100 5524232 http://www.medworm.com/index.php?rid=5524231&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fnurses%2Fcontent%2Farticle%2F10165%2F2008375%3FCID%3Drss Epidemiologist Jack Cuzick, PhD, and colleagues, writing in the Journal of the National Cancer Institute in April, concluded that “tamoxifen-induced reductions in breast density can be used to identify women who will benefit the most from prophylactic treatment with this drug.” (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5524231 Mon, 19 Dec 2011 12:00:00 +0100 5524231 http://www.medworm.com/index.php?rid=5524230&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fnurses%2Fcontent%2Farticle%2F10165%2F2008393%3FCID%3Drss Researchers from Wellspring, a Canadian nonprofit organization that supports and educates people with cancer, together with a team of patient-support consultants, have developed a 1-day program that appears to have reduced emotional exhaustion and burnout in oncology nurses. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5524230 Mon, 19 Dec 2011 12:00:00 +0100 5524230 http://www.medworm.com/index.php?rid=5524229&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fimage-iq%2Fcontent%2Farticle%2F10165%2F2008633%3FCID%3Drss A 20-year-old HIV positive male presents with headache, nausea, and vomiting following a seizure. History is notable for 3 surgeries to remove colonic polyps. Subsequent MRI brain scan with contrast reveals a mass in the left frontal lobe which is removed. The image above is an H&E stained section of the mass. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5524229 Mon, 19 Dec 2011 12:00:00 +0100 5524229 http://www.medworm.com/index.php?rid=5515184&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fbreast-cancer%2Fcontent%2Farticle%2F10165%2F2007200%3FCID%3Drss The results of a study presented at the San Antonio Breast Cancer Symposium (SABCS) prompted enough controversy to warrant a statement from 3 major medical societies and an expert panel teleconference on December 14, 2011 to discuss the analysis of data presented by the MD Anderson Cancer Center physicians. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5515184 Mon, 19 Dec 2011 01:30:01 +0100 5515184 http://www.medworm.com/index.php?rid=5515185&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcancer-management%2Foncologic-emergencies%2Farticle%2F10165%2F1802863%3FCID%3Drss This management guide for oncologic emergencies and paraneoplastic syndromes covers superior vena cava syndrome, venous thromboembolic complications, spinal cord compression, hypercalcemia, hyperuricemia, tumor lysis syndrome, SIADH, Lambert-Eaton syndrome, polymyositis, and dermatomyositis (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5515185 Fri, 16 Dec 2011 12:00:00 +0100 5515185 http://www.medworm.com/index.php?rid=5504438&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcancer-management%2Fovarian%2Farticle%2F10165%2F1802681%3FCID%3Drss This treatment guide covers the epidemiology, etiology and risk factors, signs and symptoms, screening and diagnosis, pathology, staging and prognosis, and treatment of ovarian cancer. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5504438 Fri, 16 Dec 2011 01:30:01 +0100 5504438 http://www.medworm.com/index.php?rid=5504439&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fash2011%2Fcontent%2Farticle%2F10165%2F2006526%3FCID%3Drss Results of the phase III SWOG S0016 trial comparing 2 chemotherapy regimens for follicular lymphoma (FL), presented this week at ASH, show no statistically significant differences in either progression-free survival (PFS) or overall survival. Both regimens produced “excellent” results, according to the presenter. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5504439 Thu, 15 Dec 2011 12:00:00 +0100 5504439 http://www.medworm.com/index.php?rid=5504443&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fash2011%2Fcontent%2Farticle%2F10165%2F2006013%3FCID%3Drss Updated findings from a multicenter phase Ib/II clinical trial suggest that the novel Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 may be an important new targeted treatment approach for patients with chronic lymphocytic leukemia. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5504443 Wed, 14 Dec 2011 12:00:00 +0100 5504443 http://www.medworm.com/index.php?rid=5504442&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fash2011%2Fcontent%2Farticle%2F10165%2F2005634%3FCID%3Drss The phase III randomized RESORT (ECOG Protocol E4402) trial asked whether a maintenance schedule of rituximab every 3 months would lead to a superior disease control outcome compared to retreatment upon progression. The answer, presented this week at ASH, is no. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5504442 Wed, 14 Dec 2011 12:00:00 +0100 5504442 http://www.medworm.com/index.php?rid=5504441&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fash2011%2Fcontent%2Farticle%2F10165%2F2006049%3FCID%3Drss Researchers presented a late-breaking abstract reporting activity in a metastatic lymphoma mouse model of two monoclonal antibodies combined with CpG, a short synthetic oligonucleotide agonist of TLR9, that mimic bacterial and viral DNA and facilitates a pro-inflammatory immune response. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5504441 Wed, 14 Dec 2011 12:00:00 +0100 5504441 http://www.medworm.com/index.php?rid=5504440&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fash2011%2Fcontent%2Farticle%2F10165%2F2006099%3FCID%3Drss Romiplostim, a synthetic protein that binds to and stimulates the thrombopoietin receptor, induced a rapid platelet response in adult patients with primary immune thrombocytopenia (ITP) and maintained a consistent safety profile in an international phase III trial. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5504440 Wed, 14 Dec 2011 12:00:00 +0100 5504440 http://www.medworm.com/index.php?rid=5504446&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fash2011%2Fcontent%2Farticle%2F10165%2F2005126%3FCID%3Drss The phase III trial comparing the use of gemtuzumab ozogamicin combined with chemotherapy to chemotherapy alone in newly diagnosed acute myeloid leukemia (AML) patients provides evidence that the combination treatment may be promising in this patient population. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5504446 Tue, 13 Dec 2011 12:00:00 +0100 5504446 http://www.medworm.com/index.php?rid=5504445&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fash2011%2Fcontent%2Farticle%2F10165%2F2005443%3FCID%3Drss Obinutuzumab (GA101) achieved higher response rates than rituximab in the first head-to-head trial of the two biologic agents in patients with relapsed non-Hodgkin lymphoma. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5504445 Tue, 13 Dec 2011 12:00:00 +0100 5504445 http://www.medworm.com/index.php?rid=5504444&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fash2011%2Fcontent%2Farticle%2F10165%2F2005502%3FCID%3Drss Encouraging findings were reported from multiple studies of ibritumomab tiuxetan (Zevalin), a CD20-directed radiotherapeutic antibody, in diverse patient groups with follicular lymphoma. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5504444 Tue, 13 Dec 2011 12:00:00 +0100 5504444 http://www.medworm.com/index.php?rid=5494733&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fash2011%2Fcontent%2Farticle%2F10165%2F2004956%3FCID%3Drss The first plenary session at this year’s ASH was kicked off by the presentation of a study that showed that when stem cells come from donors unrelated to the patient there is no difference in patient survival between the use of cells sourced from peripheral blood or bone marrow. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5494733 Tue, 13 Dec 2011 01:30:02 +0100 5494733 http://www.medworm.com/index.php?rid=5494735&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fsabcs2011%2Fcontent%2Farticle%2F10165%2F2004507%3FCID%3Drss Bevacizumab (Avastin) improved progression-free survival (PFS) in women with HER2-positive locally recurrent or metastatic breast cancer by an average of 3 months when added to standard treatment as first-line therapy in the multinational, randomized, phase III AVEREL study. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5494735 Mon, 12 Dec 2011 12:00:00 +0100 5494735 http://www.medworm.com/index.php?rid=5494734&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fsabcs2011%2Fcontent%2Farticle%2F10165%2F2004594%3FCID%3Drss Results of 4 trials involving bisphosphonates suggest that the role of these agents in preventing recurrence of breast cancer remains to be defined. In 2 studies reported, favorable outcomes were obtained following subcutaneous administration of zoledronic acid, but neither of two trials in which a bisphosphonate was administered orally, however, achieved its primary endpoint. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5494734 Mon, 12 Dec 2011 12:00:00 +0100 5494734 http://www.medworm.com/index.php?rid=5494736&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fash2011%2Fcontent%2Farticle%2F10165%2F2002762%3FCID%3Drss Andrew Evens, DO, MSc, deputy director for clinical and translational research and medical director of the Clinical Research Office at the UMass Memorial Health Care Cancer Center of Excellence, talks about his research on lymphoma during pregnancy. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5494736 Sun, 11 Dec 2011 12:00:00 +0100 5494736 http://www.medworm.com/index.php?rid=5486516&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fimage-iq%2Fcontent%2Farticle%2F10165%2F2004005%3FCID%3Drss A 48-year-old African American female presents with severe uterine bleeding. She states that she has been bleeding very heavily for the past two days and the flow is increasing. She is also diabetic and hypertensive. Pelvic examination revealed an enlarged irregularly shaped uterus. A large mass was noted by ultrasonography and the uterus was removed. A section of the mass is evaluated. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5486516 Sat, 10 Dec 2011 02:00:01 +0100 5486516 http://www.medworm.com/index.php?rid=5486518&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fsabcs2011%2Fcontent%2Farticle%2F10165%2F2003285%3FCID%3Drss Updated findings from the pivotal phase III Breast Cancer Trials of Oral Everolimus (BOLERO-2) study confirm dramatic improvement in progression-free survival in women with metastatic breast cancer when the immunosuppressant agent is combined with the hormonal therapy exemestane. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5486518 Fri, 09 Dec 2011 12:00:00 +0100 5486518 http://www.medworm.com/index.php?rid=5486517&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpractice%2Fcontent%2Farticle%2F10165%2F2003805%3FCID%3Drss The episode-of-care project is the first program in which a payer has partnered with the oncology community to reduce costs while paying for the demanding and complex cognitive work of the medical oncologist. The episode-of-care payment system seems to be working smoothly and we have not experienced the same erosion of our income that we have seen with other payers. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5486517 Fri, 09 Dec 2011 12:00:00 +0100 5486517 http://www.medworm.com/index.php?rid=5486521&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fsabcs2011%2Fcontent%2Farticle%2F10165%2F2003102%3FCID%3Drss Addition of pertuzumab to a standard chemotherapy combination of trastuzumab and docetaxel led to a 38% reduction in risk of disease worsening or death in patients with HER2-positive metastatic breast cancer, reported investigators from the randomized, double-blind, placebo-controlled phase III CLEOPATRA study. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5486521 Thu, 08 Dec 2011 12:00:00 +0100 5486521 http://www.medworm.com/index.php?rid=5486520&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fash2011%2Fcontent%2Farticle%2F10165%2F2003242%3FCID%3Drss CancerNetwork highlights four sessions—on anaplastic large cell lymphoma, lymphoma in pregnancy, follicular lymphoma, splenic marginal zone lymphoma—you won’t want to miss from this year’s ASH. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5486520 Thu, 08 Dec 2011 12:00:00 +0100 5486520 http://www.medworm.com/index.php?rid=5486519&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fsabcs2011%2Fcontent%2Farticle%2F10165%2F2003268%3FCID%3Drss Although some preventive steps can now be taken by women to reduce environmental factors that contribute to breast cancer risk, much more research is needed to clarify the role of recognized and suspected environmental factors, according to a new report issued by the Institute of Medicine. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5486519 Thu, 08 Dec 2011 12:00:00 +0100 5486519 http://www.medworm.com/index.php?rid=5476251&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fsabcs2011%2Fcontent%2Farticle%2F10165%2F2002211%3FCID%3Drss At this year’s San Antonio Breast Cancer Symposium, new data results from four different clinical trials of bisphosphonate usage in patients with breast cancer will be presented and discussed. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5476251 Wed, 07 Dec 2011 02:00:02 +0100 5476251 http://www.medworm.com/index.php?rid=5476253&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fimage-iq%2Fderm%2Fcontent%2Farticle%2F10165%2F2001232%3FCID%3Drss A 60-year-old woman developed metastatic renal cell carcinoma and was given oral sorafenib. Three weeks after commencing treatment, the patient became febrile without signs of localized infection and rapidly developed a nonpruritic, slightly tender cutaneous eruption. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5476253 Mon, 05 Dec 2011 12:00:00 +0100 5476253 http://www.medworm.com/index.php?rid=5476252&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fsabcs2011%2Fcontent%2Farticle%2F10165%2F2001605%3FCID%3Drss The San Antonio Breast Cancer Symposium brings together basic science researchers and clinicians for the latest breast cancer research-related progress. The symposium has evolved from a 1-day local conference to a 5-day international meeting focusing on clinical, preventive, diagnostic, translational, and basic research. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5476252 Mon, 05 Dec 2011 12:00:00 +0100 5476252 http://www.medworm.com/index.php?rid=5468533&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fblog%2Fhematology-letters%2Fcontent%2Farticle%2F10165%2F2000229%3FCID%3Drss Two recent reports show that the prognosis of MDS patients after secondary failure of hypomethylating drugs is poor, and switching from one failing hypomethylating drug to another cannot induce clinically significant responses. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5468533 Sun, 04 Dec 2011 01:30:01 +0100 5468533 http://www.medworm.com/index.php?rid=5468535&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fblog%2Fcontent%2Farticle%2F10165%2F2000255%3FCID%3Drss As insurers, clinicians and the U.S. government attempt to slow the increasing rise of health care costs, many experts have identified the tool entitled “clinical pathways” as a solution. Oncologists who adhere to such pathways are thought to improve patient care and reduce expenses. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5468535 Fri, 02 Dec 2011 12:00:00 +0100 5468535 http://www.medworm.com/index.php?rid=5468534&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fsabcs2011%2Fcontent%2Farticle%2F10165%2F2000901%3FCID%3Drss CancerNetwork interviews Kent Osborne, who is the moderator of the year in review session. He has been involved with the meeting since its beginning. The international San Antonio Breast Cancer Symposium is unique as it facilitates the interaction of both basic and science researchers and clinicians to combine the efforts of laboratory research and clinical research for better treatment and patient care. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5468534 Fri, 02 Dec 2011 12:00:00 +0100 5468534 http://www.medworm.com/index.php?rid=5457120&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpalliative-and-supportive-care%2Fcontent%2Farticle%2F10165%2F1996007%3FCID%3Drss The review by Alesi et al attempts to answer an important question in real clinical practice: Is it better to refer patients directly to hospice when aggressive treatments have stopped working or rather to integrate palliative care (PC) earlier in the course of a patient’s disease? (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5457120 Thu, 01 Dec 2011 01:30:01 +0100 5457120 http://www.medworm.com/index.php?rid=5457134&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcancer-management%2Fhematopoietic-cell-transplantation%2Farticle%2F10165%2F1802824%3FCID%3Drss This treatment guide on hematopoietic cell transplantation covers the types of transplantation, collections of the graft, indications for transplantation, timing of transplantation, phases of transplantation, management of relapse, and managing a second malignancy. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5457134 Wed, 30 Nov 2011 12:00:00 +0100 5457134 http://www.medworm.com/index.php?rid=5457133&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpalliative-and-supportive-care%2Fcontent%2Farticle%2F10165%2F1995330%3FCID%3Drss There has been much progress in our “war on cancer,” launched with President Nixon’s signing of the National Cancer Act in 1971. In 2011, however, it is estimated that more than 571,000 people will die from cancer. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5457133 Wed, 30 Nov 2011 12:00:00 +0100 5457133 http://www.medworm.com/index.php?rid=5457132&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpalliative-and-supportive-care%2Fcontent%2Farticle%2F10165%2F1995335%3FCID%3Drss As Dennis et al demonstrate, palliative care (PC) is a unique and multifaceted philosophy of care geared towards patients living with serious illness, not only those dying from it. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5457132 Wed, 30 Nov 2011 12:00:00 +0100 5457132 http://www.medworm.com/index.php?rid=5457131&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpalliative-and-supportive-care%2Fcontent%2Farticle%2F10165%2F1995340%3FCID%3Drss n their article, Dennis et al call for timely integration of palliative care into standard oncology care and sustained collaboration between these two specialties, to provide comprehensive, individualized care for patients with advanced, incurable cancer and their families. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5457131 Wed, 30 Nov 2011 12:00:00 +0100 5457131 http://www.medworm.com/index.php?rid=5457130&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpalliative-and-supportive-care%2Fcontent%2Farticle%2F10165%2F1995347%3FCID%3Drss Doctors von Gunten, Lutz, and Ferris accurately point out some of the reasons for the tragic underutilization of hospice care and ways oncologists might address this issue. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5457130 Wed, 30 Nov 2011 12:00:00 +0100 5457130 http://www.medworm.com/index.php?rid=5457129&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpalliative-and-supportive-care%2Fcontent%2Farticle%2F10165%2F1995353%3FCID%3Drss Authors von Gunten, Lutz, and Ferris have provided oncologists, and all physicians with patients who have cancer, an excellent and pithy review of how those with very advanced cancer are currently cared for as they approach the end-of-life (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5457129 Wed, 30 Nov 2011 12:00:00 +0100 5457129 http://www.medworm.com/index.php?rid=5457128&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpalliative-and-supportive-care%2Fcontent%2Farticle%2F10165%2F1994307%3FCID%3Drss Every stakeholder in the process of healthcare delivery is looking for meaningful benefit, in which the patient's quality of life is improved. Palliative care, by definition, provides meaningful benefit in the treatment of every phase of cancer. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5457128 Wed, 30 Nov 2011 12:00:00 +0100 5457128 http://www.medworm.com/index.php?rid=5457127&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpalliative-and-supportive-care%2Fcontent%2Farticle%2F10165%2F1994313%3FCID%3Drss This article will review the overlap between palliative care and oncology and discuss the available evidence that true integration of palliative and oncology care provides patients with optimal oncology care. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5457127 Wed, 30 Nov 2011 12:00:00 +0100 5457127 http://www.medworm.com/index.php?rid=5457126&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpalliative-and-supportive-care%2Fcontent%2Farticle%2F10165%2F1994323%3FCID%3Drss This article highlights the importance of palliative cancer care and the palliative care specialist to patients with incurable cancer. Oncology treatment programs have difficulty assessing and managing the many domains of care required by these patients, making collaboration across disciplines critical. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5457126 Wed, 30 Nov 2011 12:00:00 +0100 5457126 http://www.medworm.com/index.php?rid=5457125&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpalliative-and-supportive-care%2Fcontent%2Farticle%2F10165%2F1994328%3FCID%3Drss In this article, prognostic data are summarized and a suggested approach for discussing hospice enrollment with patients is presented. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5457125 Wed, 30 Nov 2011 12:00:00 +0100 5457125 http://www.medworm.com/index.php?rid=5457124&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpalliative-and-supportive-care%2Fcontent%2Farticle%2F10165%2F1994333%3FCID%3Drss This article addresses the practical application of palliative care (PC) in the outpatient oncology setting. While information on this topic is scarce, data published by a few outpatient practices provide the basis for potential models of integrated care. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5457124 Wed, 30 Nov 2011 12:00:00 +0100 5457124 http://www.medworm.com/index.php?rid=5457123&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpalliative-and-supportive-care%2Fcontent%2Farticle%2F10165%2F1995792%3FCID%3Drss First, I need to reiterate what Dr. Alesi and her coauthors have so clearly stated: that there is a paucity of published data on most aspects of the delivery of palliative care (PC) services in the outpatient setting, although this now appears to be changing. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5457123 Wed, 30 Nov 2011 12:00:00 +0100 5457123 http://www.medworm.com/index.php?rid=5457122&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpalliative-and-supportive-care%2Fcontent%2Farticle%2F10165%2F1995797%3FCID%3Drss The demand for early palliative care (PC) involvement has never been greater in the setting of capitated healthcare delivery systems. The review by Alesi et al is timely in that it illustrates innovative practice partnerships with oncology groups during a time when PC is being thrust into mainstream outpatient care.[1] (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5457122 Wed, 30 Nov 2011 12:00:00 +0100 5457122 http://www.medworm.com/index.php?rid=5457121&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fdisplay%2Farticle%2F10165%2F1995317%3FCID%3Drss In their article, Dr. Jamie Von Roenn and Dr. Jennifer Temel demonstrate the value of enhanced symptomatic and palliative care for symptom reduction, improvement in quality of life, and, in some instances, better survival. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5457121 Wed, 30 Nov 2011 12:00:00 +0100 5457121 http://www.medworm.com/index.php?rid=5457135&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fbreast-cancer%2Fcontent%2Farticle%2F10165%2F1997860%3FCID%3Drss Is estrogen plus progestin better than estrogen alone for symptom relief in menopausal women? For women who have not had a hysterectomy, adding progestin to estrogen therapy counteracts the increased risk of uterine cancer from estrogen monotherapy. However, the progestin and estrogen combination increases breast cancer risk. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5457135 Tue, 29 Nov 2011 12:00:00 +0100 5457135 http://www.medworm.com/index.php?rid=5457138&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fimage-iq%2Fcontent%2Farticle%2F10165%2F1997693%3FCID%3Drss A 41-year-old male carrying the diagnosis of Peutz-Jeghers syndrome complains of upper abdominal pain radiating to the back and a 15-pound weight loss. Laboratory studies and imaging prompt surgery. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5457138 Mon, 28 Nov 2011 12:00:00 +0100 5457138 http://www.medworm.com/index.php?rid=5457137&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fgynecologic-cancer%2Fcontent%2Farticle%2F10165%2F1997834%3FCID%3Drss Coffee is emerging as a protective agent against a number of diseases, including cancer. A study published last week shows that women who drank more than four cups of coffee per day cut their risk of endometrial cancer by 25% compared with those who drank less than one cup per day. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5457137 Mon, 28 Nov 2011 12:00:00 +0100 5457137 http://www.medworm.com/index.php?rid=5457136&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcancer-management%2Fanorexia-cachexia%2Farticle%2F10165%2F1802855%3FCID%3Drss This treatment guides covers the diagnostic criteria, management, nutritional counseling, appetite stimulants, enteral or parental stimulants, prophylactic therapy, and nutrition in end-of-life care for anorexia and cachexia. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5457136 Mon, 28 Nov 2011 12:00:00 +0100 5457136 http://www.medworm.com/index.php?rid=5440421&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fmelanoma-skin-cancer%2Fcontent%2Farticle%2F10165%2F1996126%3FCID%3Drss Immunotherapy is finally getting the cancer clinical and research community excited: A large portion of the presentation and discussion at the Melanoma International Congress, held in Tampa, Florida last week focused on immunotherapy approaches for the treatment of the disease. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5440421 Fri, 25 Nov 2011 01:30:01 +0100 5440421 http://www.medworm.com/index.php?rid=5431452&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fnurses%2Fcontent%2Farticle%2F10165%2F1995755%3FCID%3Drss In a Canadian study of more than 14,000 breast cancer survivors over 65 years of age, current use of tamoxifen appears to be associated with a small increased risk of diabetes. The findings do not mean tamoxifen is a direct cause of diabetes in this patient population, the study authors emphasized, but they said its use may increase diabetes risk in older women who already have known risk factors for diabetes, such as obesity or a family history of the disease. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5431452 Tue, 22 Nov 2011 01:30:02 +0100 5431452 http://www.medworm.com/index.php?rid=5431456&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fprostate-cancer%2Fcontent%2Farticle%2F10165%2F1985507%3FCID%3Drss This month we asked ONCOLOGY’s Editorial Board to informally weigh in on the US preventive Services Task Force’s recommendation against the routine screening of healthy men with the prostate-specific antigen (PSA) test. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5431456 Mon, 21 Nov 2011 12:00:00 +0100 5431456 http://www.medworm.com/index.php?rid=5431455&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fimage-iq%2Fderm%2Fcontent%2Farticle%2F10165%2F1995221%3FCID%3Drss A 29-year-old man was presented early in this series as an example of stage IV, poorly differentiated malignant melanoma. As noted previously, evaluation disclosed the presence of multifocal metastatic disease (lungs, lymph nodes). (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5431455 Mon, 21 Nov 2011 12:00:00 +0100 5431455 http://www.medworm.com/index.php?rid=5431454&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fnurses%2Fcontent%2Farticle%2F10165%2F1995455%3FCID%3Drss The often-weakened immune systems of cancer patients receiving chemotherapy put them at greater risk of acquiring life-threatening infections in community and hospital settings, including during appointments for outpatient treatment. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5431454 Mon, 21 Nov 2011 12:00:00 +0100 5431454 http://www.medworm.com/index.php?rid=5431453&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fnurses%2Fcontent%2Farticle%2F10165%2F1995725%3FCID%3Drss A survey of more than 500 long-term survivors of non-Hodgkin’s lymphoma (NHL) has revealed that more than one-third experience persistent or worsening symptoms of post-traumatic stress disorder (PTSD), with nearly 4 of 10 cancer survivors stating they still experience symptoms of PTSD more than a decade after their cancer diagnosis. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5431453 Mon, 21 Nov 2011 12:00:00 +0100 5431453 http://www.medworm.com/index.php?rid=5421737&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fbreast-cancer%2Fcontent%2Farticle%2F10165%2F1994301%3FCID%3Drss The US Food and Drug Administration announced today that it has revoked the approval of bevacizumab for breast cancer due to the potentially life-threatening side effects associated with the treatment. It was approved for metastatic breast cancer in February 2008, but data later showed that along with an increase in side effects, there was no increase in overall survival. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5421737 Sat, 19 Nov 2011 01:30:02 +0100 5421737 http://www.medworm.com/index.php?rid=5421739&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fmelanoma-skin-cancer%2Fcontent%2Farticle%2F10165%2F1993432%3FCID%3Drss The theme of the SMR meeting in Tampa this year was “Advancement through Collaboration," and this theme was clearly reflected in the meeting. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5421739 Thu, 17 Nov 2011 12:00:00 +0100 5421739 http://www.medworm.com/index.php?rid=5421738&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fblog%2Fcontent%2Farticle%2F10165%2F1993709%3FCID%3Drss Nationally, the number of drug shortages has tripled since 2005. Other generic drug shortages in our clinic have included paclitaxel, leucovorin, and doxorubicin. We have had limited access to ordering 5-FU and mitomycin. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5421738 Thu, 17 Nov 2011 12:00:00 +0100 5421738 http://www.medworm.com/index.php?rid=5407361&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpractice%2Fcontent%2Farticle%2F10165%2F1985552%3FCID%3Drss The article by Aneja, Gross, Soulos, and Yu outlines applications of geographical information systems (GIS) software to oncology research. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5407361 Wed, 16 Nov 2011 17:00:02 +0100 5407361 http://www.medworm.com/index.php?rid=5407368&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fmelanoma-skin-cancer%2Fcontent%2Farticle%2F10165%2F1985465%3FCID%3Drss With the potential for therapeutic durability and a small chance of cure, surgical resection may offer improved survival compared to other therapeutic modalities. This review summarizes the existing literature that addresses the topic of metastasectomy in patients with melanoma and breast cancer. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5407368 Tue, 15 Nov 2011 12:00:00 +0100 5407368 http://www.medworm.com/index.php?rid=5407367&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fmelanoma-skin-cancer%2Fcontent%2Farticle%2F10165%2F1985490%3FCID%3Drss In the absence of level I evidence (which does not exist for resection of colorectal liver metastases either), clinicians must use an abundance of clinical judgment in selecting patients with melanoma or breast cancer for liver resection. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5407367 Tue, 15 Nov 2011 12:00:00 +0100 5407367 http://www.medworm.com/index.php?rid=5407366&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fsarcoma%2Fcontent%2Farticle%2F10165%2F1985515%3FCID%3Drss This article provides an extensive review of patient selection criteria and surgical approaches, as well as of controversies regarding resection for metastatic sarcoma. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5407366 Tue, 15 Nov 2011 12:00:00 +0100 5407366 http://www.medworm.com/index.php?rid=5407365&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fsarcoma%2Fcontent%2Farticle%2F10165%2F1985522%3FCID%3Drss Isolated pulmonary metastases represent a unique manifestation of the myriad presentations of systemic spread from a primary neoplasm. Selected patients with metastases isolated within an organ system that has significant reserve can have these metastases resected safely with a number of different surgical techniques. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5407365 Tue, 15 Nov 2011 12:00:00 +0100 5407365 http://www.medworm.com/index.php?rid=5407364&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fsarcoma%2Fcontent%2Farticle%2F10165%2F1985531%3FCID%3Drss Biological factors appear to predominate in the management of patients with this difficult development, whether it arises from osteosarcoma, from other bone tumors, or from soft-tissue sarcomas. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5407364 Tue, 15 Nov 2011 12:00:00 +0100 5407364 http://www.medworm.com/index.php?rid=5407363&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fsarcoma%2Fcontent%2Farticle%2F10165%2F1985540%3FCID%3Drss Surgical resection of isolated pulmonary metastases has been incorporated into the management of cancer for more than 70 years. However, many questions still remain concerning indications, technique, and efficacy for this approach. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5407363 Tue, 15 Nov 2011 12:00:00 +0100 5407363 http://www.medworm.com/index.php?rid=5407362&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpractice%2Fcontent%2Farticle%2F10165%2F1985545%3FCID%3Drss In this review, we discuss the potential applications and limitations of GIS software in oncology research. Our aims are to help clinicians and policy makers interpret studies generated using GIS, and to help clinical investigators implement GIS in future research. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5407362 Tue, 15 Nov 2011 12:00:00 +0100 5407362 http://www.medworm.com/index.php?rid=5407372&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fpractice%2Fcontent%2Farticle%2F10165%2F1985437%3FCID%3Drss This article summarizes some of the most important federal coverage provisions and safeguards that promote access to preventive services for individuals with cancer or individuals who are at risk for cancer. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5407372 Mon, 14 Nov 2011 12:00:00 +0100 5407372 http://www.medworm.com/index.php?rid=5407371&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fleukemia-lymphoma%2Fcontent%2Farticle%2F10165%2F1985442%3FCID%3Drss Treatment aimed at eradicating H pylori infection results in remission of gastric MALT lymphoma in most patients and represents a model of anticancer treatment based on the eradication of the causative factor. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5407371 Mon, 14 Nov 2011 12:00:00 +0100 5407371 http://www.medworm.com/index.php?rid=5407370&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fleukemia-lymphoma%2Fcontent%2Farticle%2F10165%2F1985455%3FCID%3Drss Normal B lymphocytes can follow either of two functionally distinct pathways of development. The first is a classical germinal center T-dependent pathway in which diversification and maturation generate a delayed but almost unlimited high-affinity response to antigens. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5407370 Mon, 14 Nov 2011 12:00:00 +0100 5407370 http://www.medworm.com/index.php?rid=5407369&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fmelanoma-skin-cancer%2Fcontent%2Farticle%2F10165%2F1990521%3FCID%3Drss With positive read-outs from trials over the last two years and approval of two new agents for the disease, Yervoy and Zelboraf, the field is already looking to new agents and combination trials to improve patient outcomes and survival. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5407369 Mon, 14 Nov 2011 12:00:00 +0100 5407369 http://www.medworm.com/index.php?rid=5400384&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fconference-reports%2Fasco2011%2Farticle%2F10165%2F1989798%3FCID%3Drss Blase Polite, MD, assistant professor of medicine at the University of Chicago and the track leader for the GI Colorectal Scientific Program Committee at ASCO, discusses the latest research in the field of colorectal cancer. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400384 Sun, 13 Nov 2011 01:30:01 +0100 5400384 http://www.medworm.com/index.php?rid=5400386&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcancer-management%2Ffatigue-dyspnea%2Farticle%2F10165%2F1802849%3FCID%3Drss This guide covers the mechanism, clinical features, assessment, and management of fatigue and dyspnea. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400386 Fri, 11 Nov 2011 12:00:00 +0100 5400386 http://www.medworm.com/index.php?rid=5400385&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fbreast-cancer%2Fcontent%2Farticle%2F10165%2F1989588%3FCID%3Drss The results of a trial comparing concurrent versus sequential trastuzumab and chemotherapy as adjuvant treatment of breast cancer has shown an improved efficacy without increased toxicity for the concurrent regimen. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400385 Fri, 11 Nov 2011 12:00:00 +0100 5400385 http://www.medworm.com/index.php?rid=5400390&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcancer-management%2Fchronic-myeloid-leukemia%2Farticle%2F10165%2F1802798%3FCID%3Drss Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder resulting from the neoplastic transformation of the primitive hematopoietic stem cell. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400390 Thu, 10 Nov 2011 12:00:00 +0100 5400390 http://www.medworm.com/index.php?rid=5400389&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcancer-management%2Fmds%2Farticle%2F10165%2F1802819%3FCID%3Drss This treatment guide covers the epidemiology, etiology and risk factors, classification, signs and symptoms, staging and prognosis, and the treatment of myelodysplastic syndromes. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400389 Thu, 10 Nov 2011 12:00:00 +0100 5400389 http://www.medworm.com/index.php?rid=5400388&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcancer-management%2Fnausea-vomiting%2Farticle%2F10165%2F1802844%3FCID%3Drss This management guide covers the pathophysiology of emesis, emetic problems, patient characteristics and emesis, chemotherapeutic agents and emesis, antiemetic agents for high-emetic-risk chemotherapy, combination antiemetic regimens, and the treatment of emesis. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400388 Thu, 10 Nov 2011 12:00:00 +0100 5400388 http://www.medworm.com/index.php?rid=5400387&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fbreast-cancer%2Fcontent%2Farticle%2F10165%2F1988943%3FCID%3Drss Breast and ovarian cancer patients with limited tumor burden and minimal prior chemotherapy appear to have benefited from a novel vaccine, according to trial results just published in Clinical Cancer Research. This trial, and especially the over 3-year sustained response of a patient with advanced breast cancer shows the potential of a therapeutic vaccine for improved outcomes in a selective subset of patients. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400387 Thu, 10 Nov 2011 12:00:00 +0100 5400387 http://www.medworm.com/index.php?rid=5400392&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcancer-management%2Fmyeloma%2Farticle%2F10165%2F1802756%3FCID%3Drss Multiple myeloma is a disseminated malignancy of monoclonal plasma cells that accounts for 15% of all hematologic cancers. In 2010, an estimated 20,180 new cases will be diagnosed in the United States, and 10,650 Americans will die of this disease. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400392 Wed, 09 Nov 2011 12:00:00 +0100 5400392 http://www.medworm.com/index.php?rid=5400391&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcancer-management%2Fchronic-lymphocytic-leukemia%2Farticle%2F10165%2F1802781%3FCID%3Drss This management guide covers the epidemiology, etiology and risk factors, signs and symptoms, laboratory features, cytogenetic and molecular findings, staging and prognosis, and treatment of chronic lymphocytic leukemia, as well as the treatment of hairy-cell leukemia. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400391 Wed, 09 Nov 2011 12:00:00 +0100 5400391 http://www.medworm.com/index.php?rid=5400393&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fimage-iq%2Fcontent%2Farticle%2F10165%2F1986724%3FCID%3Drss A 22-year-old female collegiate soccer player complains of a painful palpable area in her right breast accompanied by a straw-colored nipple discharge. Because she is extremely anxious and has had previous excisional biopsies, you decide to perform a lumpectomy. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400393 Tue, 08 Nov 2011 12:00:00 +0100 5400393 http://www.medworm.com/index.php?rid=5400402&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fsupplements%2Fonc-nov-2011%2Fcontent%2Farticle%2F10165%2F1983363%3FCID%3Drss The goal of this supplement is to present a comprehensive overview of the major current and emerging treatment options for patients with relapsed and/or refractory MM, with particular focus on proteasome inhibitors and immunomodulatory drugs, along with other emerging agents (eg, histone deacetylase inhibitors, heat shock protein inhibitors, and monoclonal antibodies). (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400402 Mon, 07 Nov 2011 12:00:00 +0100 5400402 http://www.medworm.com/index.php?rid=5400401&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fsupplements%2Fonc-nov-2011%2Fcontent%2Farticle%2F10165%2F1983377%3FCID%3Drss Advances in our knowledge of the molecular, cellular, and genetic bases of MM are leading to improvements in diagnosis, disease staging, and treatment—and these improvements are reflected in reduced mortality rates and lengthened survival durations. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400401 Mon, 07 Nov 2011 12:00:00 +0100 5400401 http://www.medworm.com/index.php?rid=5400400&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fsupplements%2Fonc-nov-2011%2Fcontent%2Farticle%2F10165%2F1983385%3FCID%3Drss This article describes the current evidence available for various treatment options as well as a personal approach to individualized therapy for relapsing patients. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400400 Mon, 07 Nov 2011 12:00:00 +0100 5400400 http://www.medworm.com/index.php?rid=5400399&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fsupplements%2Fonc-nov-2011%2Fcontent%2Farticle%2F10165%2F1983417%3FCID%3Drss Over the past decade, proteasomal inhibition has emerged as an important therapeutic strategy, and PIs represent a promising treatment option for the management of MM. Variations in the binding profiles of different PIs may translate into key differences in pharmacokinetic and toxicity profiles that may prove clinically relevant in the treatment of MM. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400399 Mon, 07 Nov 2011 12:00:00 +0100 5400399 http://www.medworm.com/index.php?rid=5400398&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fsupplements%2Fonc-nov-2011%2Fcontent%2Farticle%2F10165%2F1983430%3FCID%3Drss Over the past decade, proteasomal inhibition has emerged as an important therapeutic strategy, and PIs represent a promising treatment option for the management of MM. Variations in the binding profiles of different PIs may translate into key differences in pharmacokinetic and toxicity profiles that may prove clinically relevant in the treatment of MM. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400398 Mon, 07 Nov 2011 12:00:00 +0100 5400398 http://www.medworm.com/index.php?rid=5400397&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fsupplements%2Fonc-nov-2011%2Fcontent%2Farticle%2F10165%2F1983635%3FCID%3Drss This review will discuss the side-effect profiles of the currently approved immunomodulatory agents and bortezomib, as well as those of the newer agents, carfilzomib and pomalidomide. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400397 Mon, 07 Nov 2011 12:00:00 +0100 5400397 http://www.medworm.com/index.php?rid=5400396&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fsupplements%2Fonc-nov-2011%2Fcontent%2Farticle%2F10165%2F1983640%3FCID%3Drss This article extrapolates our current knowledge into an algorithm for the future use of proteasome inhibitors against multiple myeloma. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400396 Mon, 07 Nov 2011 12:00:00 +0100 5400396 http://www.medworm.com/index.php?rid=5400395&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fsupplements%2Fonc-nov-2011%2Fcontent%2Farticle%2F10165%2F1983667%3FCID%3Drss It is likely that in the near future the treatment armamentarium for MM will undergo a significant expansion as a number of these additional target pathways become validated, offering additional hope for extending survival in patients with MM. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400395 Mon, 07 Nov 2011 12:00:00 +0100 5400395 http://www.medworm.com/index.php?rid=5400394&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fbreast-cancer%2Fcontent%2Farticle%2F10165%2F1985851%3FCID%3Drss Researchers have developed a novel way to molecularly target and kill cancer cells, called photoimmunotherapy. The method uses a monoclonal antibody against the epidermal growth factor coupled to a near-infrared dye. The result is a target-specific photosensitizer that causes specific cell death of cells bound by the antibody when NIR light is applied. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400394 Mon, 07 Nov 2011 12:00:00 +0100 5400394 http://www.medworm.com/index.php?rid=5400403&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fimage-iq%2Fderm%2Fcontent%2Farticle%2F10165%2F1984709%3FCID%3Drss A 56-year-old man with renal cell carcinoma developed widely metastatic disease post nephrectomy, for which he was receiving cyclic sunitinib therapy (50 mg daily for 4 weeks, followed by a 2-week rest period). Toward the end of his second cycle of therapy, he developed minimally pruritic, bright red erythema and fine scale involving both sides of the scrotum. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5400403 Fri, 04 Nov 2011 12:00:00 +0100 5400403 http://www.medworm.com/index.php?rid=5360064&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcancer-management%2Faids-malignancies%2Farticle%2F10165%2F1802726%3FCID%3Drss Malignancies have been detected in approximately 40% of all patients with acquired immunodeficiency syndrome (AIDS) sometime during the course of their illness. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5360064 Mon, 31 Oct 2011 00:00:02 +0100 5360064 http://www.medworm.com/index.php?rid=5360067&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcancer-management%2Fpancreatic%2Farticle%2F10165%2F1802606%3FCID%3Drss This treatment guide covers the incidence, epidemiology, etiology and risk factors, signs and symptoms, screening, diagnosis, pathology, staging, prognosis, and the treatment of pancreatic cancer as well as covering pancreatic cystic neoplasms, pancreatic endocrine tumors (PETs), carcinoid tumors of the GI tract, adrenocortical carcinoma, and pheochromocytoma. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5360067 Fri, 28 Oct 2011 12:00:00 +0100 5360067 http://www.medworm.com/index.php?rid=5360066&cid=s_38279_6_f&fid=38279&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcancer-management%2Fcervical%2Farticle%2F10165%2F1802664%3FCID%3Drss Of the predominant gynecologic cancers, cancer of the uterine cervix is the least common, with only 12,200 new cases anticipated in the United States in 2010. Nevertheless, approximately 4,210 women die of cancer of the uterine cervix annually in the United States. (Source: Cancer Network) Cancer Network news http://www.medworm.com/rss/comments.php?id=5360066 Fri, 28 Oct 2011 12:00:00 +0100 5360066